Tumour chemotherapy sensitivity test may predict clinical outcomes in colorectal cancer patients receiving oxaliplatin and fluoropyrimidine-based regimens

Figure 1 Flow chart of the study design. ATP-TCA: Adenosine triphosphate-based tumour chemotherapy sensitivity test; OS: Overall survival; DFS: Disease-free survival.

Figure 2 Kaplan-Meier survival curves to evaluate the survival outcomes of patients in the validation set. A: Disease-free survival outcomes of patients in the validation set; B: Overall survival outcomes of patients in the validation set. ^aP < 0.05.

Figure 3 Clinical prediction model for disease-free survival in patients with colorectal cancer. A: Nomogram of disease-free survival (DFS) outcomes; B: Receiver operating characteristic of the clinical prediction model for 3-year DFS; C: Receiver operating characteristic curve of the clinical prediction model for 5-year DFS; D: Calibration curve for the clinical prediction model for 3-year DFS outcomes; E: Calibration curve for the clinical prediction model for 5-year DFS outcomes; F: Decision curve analysis (DCA) of the clinical prediction model for 3-year DFS in the training set; G: DCA of the clinical prediction model for 5-year DFS in the training set; H: DCA of the clinical prediction model for 3-year DFS in the validation set; I: DCA of the clinical prediction model for 5-year DFS in the training set. ATP-TCA: Adenosine triphosphate-based tumour chemotherapy sensitivity test; DFS: Disease-free survival; AUC: Area under the curve; CI: Confidence interval.

Figure 4 Kaplan-Meier survival curves for evaluating the survival outcomes of patients diagnosed with stage II or III colorectal cancer. A: Overall survival outcomes of patients with stage II colorectal cancer (CRC); B: Disease-free survival outcomes of patients with stage II CRC; C: Overall survival outcomes of patients with stage III CRC; D: Disease-free survival outcomes of patients with stage III CRC. ^aP < 0.05, ^bP < 0.01.